Physician profile
Perdita Permaul
NPI 1518127265
$888.44
in general payments reported to CMS, 2019-2025
8 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $126 · 2021: $82.63 · 2022: $49.95 · 2024: $214 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $224.41 | 2025 | |
| Alk-Abello, INC | $208.92 | 2020-2021 | |
| Genentech USA, INC. | $144.98 | 2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $142.89 | 2025 | |
| Pfizer INC. | $49.95 | 2022 | |
| Csl Behring | $47.97 | 2025 | Hizentra |
| Biocryst US Sales Co., LLC | $36.00 | 2024 | Orladeyo |
| Dermavant Sciences, INC. | $33.32 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perdita Permaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.